cropped-cropped-cropped-Logo-maker-project-1.png
GMP Updates

PIC/S PE009-18: What’s New in the Latest GMP Guide — And How It Compares to PE009-16

The Pharmaceutical Inspection Co-operation Scheme (PIC/S) continues to enhance global GMP standards through its evolving guide. While Australia currently enforces PE009-16 (as of February 2022), the most recent PIC/S version is PE009-18, adopted internationally by some regulatory bodies from 1 February 2022.

So, what’s changed in PE009-18, and how does it compare to PE009-16? Let’s break it down for quality professionals, manufacturers, and consultants keeping an eye on future compliance trends.


What Is PIC/S PE009-18?

PE009-18 is the latest revision of the PIC/S Guide to GMP for Medicinal Products, incorporating updates to support:


    PE009-18 vs PE009-16 — Key Differences at a Glance

    Focus AreaPE009-16PE009-18
    Annex 1 - Sterile ManufacturingLegacy versionRefreshed version adopted (2023): heavy focus on Contamination Control Strategy (CCS)
    QRM (Quality Risk Management)Stronger focus addedExpanded integration across entire lifecycle (aligned with ICH Q9(R1))
    Data IntegrityReinforced in Chapter 4Further aligned with MHRA & FDA expectations, including audit trails, access controls
    Product Quality Review (PQR)Required annuallyEnhanced expectations for data trending and CAPA linkage
    Supplier QualificationStrengthened under PE009-16Further detailed in Annex 8 with risk-based supplier management strategies
    Pharmaceutical Quality System (PQS)Defined in Chapter 1Now demands continuous improvement and alignment with ICH Q10
    Computerised SystemsAddressed in Annex 11Harmonized expectations on cloud-based systems, backups, and electronic batch records

    Is PIC/S PE009-18 Mandatory in Australia?

    Not yet. The TGA currently enforces PE009-16, and there has been no formal announcement (as of May 2025) of adoption of version 18.

    However, forward-thinking manufacturers should start preparing for the inevitable. With many global regulators (e.g. Swissmedic, HPRA, and TFDA) already referring to PE009-17 or 18, Australian manufacturers may need to adopt newer standards in the near future.


    Action Plan: Future-Proof Your Compliance